Stepanova et al., 2012 - Google Patents
Association of hepatitis C with insulin resistance and type 2 diabetes in US general population: the impact of the epidemic of obesityStepanova et al., 2012
- Document ID
- 2521107738996141270
- Author
- Stepanova M
- Lam B
- Younossi Y
- Srishord M
- Younossi Z
- Publication year
- Publication venue
- Journal of viral hepatitis
External Links
Snippet
Studies from tertiary care medical centres have linked hepatitis C virus (HCV) to the development of insulin resistance (IR) and type 2 diabetes. The aim of the study is to assess the relationship between HCV positivity and insulin resistance/diabetes in the US …
- 206010022489 Insulin resistance 0 title abstract description 58
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay
- G01N33/576—Immunoassay; Biospecific binding assay for hepatitis
- G01N33/5767—Immunoassay; Biospecific binding assay for hepatitis non-A, non-B hepatitis
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING; COUNTING
- G06Q—DATA PROCESSING SYSTEMS OR METHODS, SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL, SUPERVISORY OR FORECASTING PURPOSES; SYSTEMS OR METHODS SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL, SUPERVISORY OR FORECASTING PURPOSES, NOT OTHERWISE PROVIDED FOR
- G06Q50/00—Systems or methods specially adapted for a specific business sector, e.g. utilities or tourism
- G06Q50/10—Services
- G06Q50/22—Health care, e.g. hospitals; Social work
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING; COUNTING
- G06F—ELECTRICAL DIGITAL DATA PROCESSING
- G06F19/00—Digital computing or data processing equipment or methods, specially adapted for specific applications
- G06F19/30—Medical informatics, i.e. computer-based analysis or dissemination of patient or disease data
- G06F19/32—Medical data management, e.g. systems or protocols for archival or communication of medical images, computerised patient records or computerised general medical references
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING; COUNTING
- G06F—ELECTRICAL DIGITAL DATA PROCESSING
- G06F19/00—Digital computing or data processing equipment or methods, specially adapted for specific applications
- G06F19/30—Medical informatics, i.e. computer-based analysis or dissemination of patient or disease data
- G06F19/34—Computer-assisted medical diagnosis or treatment, e.g. computerised prescription or delivery of medication or diets, computerised local control of medical devices, medical expert systems or telemedicine
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING; COUNTING
- G06F—ELECTRICAL DIGITAL DATA PROCESSING
- G06F19/00—Digital computing or data processing equipment or methods, specially adapted for specific applications
- G06F19/30—Medical informatics, i.e. computer-based analysis or dissemination of patient or disease data
- G06F19/36—Computer-assisted acquisition of medical data, e.g. computerised clinical trials or questionnaires
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING; COUNTING
- G06Q—DATA PROCESSING SYSTEMS OR METHODS, SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL, SUPERVISORY OR FORECASTING PURPOSES; SYSTEMS OR METHODS SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL, SUPERVISORY OR FORECASTING PURPOSES, NOT OTHERWISE PROVIDED FOR
- G06Q50/00—Systems or methods specially adapted for a specific business sector, e.g. utilities or tourism
- G06Q50/01—Social networking
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Stepanova et al. | Association of hepatitis C with insulin resistance and type 2 diabetes in US general population: the impact of the epidemic of obesity | |
Bartlett et al. | The population level care cascade for hepatitis C in British Columbia, Canada as of 2018: impact of direct acting antivirals | |
Gomez et al. | Sex differences in COVID-19 hospitalization and mortality | |
Younossi et al. | Associations of chronic hepatitis C with metabolic and cardiac outcomes | |
Younossi et al. | The impact of hepatitis C burden: an evidence‐based approach | |
Memon et al. | Prevalence of type 2 diabetes mellitus in hepatitis C virus infected population: a Southeast Asian study | |
Lee et al. | Chronic hepatitis C virus infection increases mortality from hepatic and extrahepatic diseases: a community-based long-term prospective study | |
Eslam et al. | Meta‐analysis: insulin resistance and sustained virological response in hepatitis C | |
Sorrell et al. | National Institutes of Health consensus development conference statement: management of hepatitis B | |
Aleman et al. | A risk for hepatocellular carcinoma persists long-term after sustained virologic response in patients with hepatitis C–associated liver cirrhosis | |
Mehta et al. | Prevalence of type 2 diabetes mellitus among persons with hepatitis C virus infection in the United States | |
Rao et al. | Distribution and clinical correlates of viral and host genotypes in C hinese patients with chronic hepatitis C virus infection | |
Tyson et al. | Prevalence and predictors of hepatitis B virus coinfection in a United States cohort of hepatitis C virus‐infected patients | |
Neal | Excess mortality rates in a cohort of patients infected with the hepatitis C virus: a prospective study | |
Deleuran et al. | Cirrhosis and mortality risks of biopsy‐verified alcoholic pure steatosis and steatohepatitis: a nationwide registry‐based study | |
Younossi et al. | Moderate, excessive or heavy alcohol consumption: each is significantly associated with increased mortality in patients with chronic hepatitis C | |
Lin et al. | Chronic hepatitis C virus infection and the risk for diabetes: a community‐based prospective study | |
Abu-Freha et al. | Chronic hepatitis C: Diagnosis and treatment made easy | |
Shahbaz et al. | Highlights of drug-and herb-induced liver injury in the literature from 2016: how best to translate new information into clinical practice? | |
Butt et al. | Changes in circulating lipids level over time after acquiring HCV infection: results from ERCHIVES | |
Rogal et al. | Incidence and progression of chronic kidney disease after hepatitis C seroconversion: results from ERCHIVES | |
Lee et al. | Polymorphisms near the IFNL3 gene associated with HCV RNA spontaneous clearance and hepatocellular carcinoma risk | |
Huang et al. | Increased risk of hepatocellular carcinoma in chronic hepatitis C patients with new onset diabetes: a nation‐wide cohort study | |
Lebwohl et al. | Risk of severe COVID-19 in patients with celiac disease: a population-based cohort study | |
Trimble et al. | Mortality associated with alcohol‐related liver disease |